Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Roivant Sciences reported significant clinical progress during its third quarter ended December 31, 2025, notably with positive Phase II results for brepocitinib in cutaneous sarcoidosis, alongside ongoing developments across its broader pipeline.</li><li>The Phase II study of brepocitinib, a TYK2/JAK1 inhibitor, demonstrated substantial efficacy in treating cutaneous sarcoidosis—a debilitating skin disease with no currently approved therapies.</li><li>The trial enrolled 31 patients randomized 3:2:2 to high-dose (45 mg), low-dose (15 mg), or placebo over 16 weeks.</li></ul>

Roivant Sciences reported significant clinical progress during its third quarter ended December 31, 2025, notably with positive Phase II results for brepocitinib in cutaneous sarcoidosis, alongside ongoing developments across its broader pipeline.The Phase II study of brepocitinib, a TYK2/JAK1 inhibitor, demonstrated substantial efficacy in treating cutaneous sarcoidosis—a debilitating skin disease with no currently approved therapies.The trial enrolled 31 patients randomized 3:2:2 to high-dose (45 mg), low-dose (15 mg), or placebo over 16 weeks.

Roivant Sciences: How Its Unique Deal Structure With Pfizer Could Shape Long-Term Value!

<ul><li>Roivant's latest quarter represents a mixed bag of significant achievements and ongoing challenges.</li><li>The company is progressing with multiple high-impact projects, showcasing a promising pipeline, but also faces competitive pressures and some uncertainties in its strategic outlook.</li><li>On the positive side, Roivant has made notable advancements in its late-stage pipeline.</li></ul>

Roivant's latest quarter represents a mixed bag of significant achievements and ongoing challenges.The company is progressing with multiple high-impact projects, showcasing a promising pipeline, but also faces competitive pressures and some uncertainties in its strategic outlook.On the positive side, Roivant has made notable advancements in its late-stage pipeline.

Roivant Sciences: From Batoclimab Breakthroughs to Global Trials—A Rising Contender in Autoimmune Therapeutics!

<ul><li>Roivant presented its financial results for the first quarter ending June 30, 2025, reflecting a period described as relatively quiet but setting the stage for significant events in the upcoming months.</li><li>The company is primarily focused on its diverse pipeline of biopharmaceutical endeavors, comprising significant R&D progressions and ongoing litigation matters.</li><li>This analysis will cover these key areas of their operational focus and financial strategy.</li></ul>

Roivant presented its financial results for the first quarter ending June 30, 2025, reflecting a period described as relatively quiet but setting the stage for significant events in the upcoming months.The company is primarily focused on its diverse pipeline of biopharmaceutical endeavors, comprising significant R&D progressions and ongoing litigation matters.This analysis will cover these key areas of their operational focus and financial strategy.

Roivant Sciences: An Insight Into The Progress in Brepocitinib Trials & Key Growth Levers!

<ul><li>Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts.</li><li>The company emphasized advancements in its late-stage pipeline, particularly in its anti-FcRn franchise and developments in brepocitinib.</li><li>The fiscal year was marked by the generation of critical data from studies involving batoclimab in Myasthenia Gravis and CIDP, as well as anticipation for pivotal data from brepocitinib in dermatomyositis, which could lead to novel treatments with significant lead-time advantages.</li></ul>

Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts.The company emphasized advancements in its late-stage pipeline, particularly in its anti-FcRn franchise and developments in brepocitinib.The fiscal year was marked by the generation of critical data from studies involving batoclimab in Myasthenia Gravis and CIDP, as well as anticipation for pivotal data from brepocitinib in dermatomyositis, which could lead to novel treatments with significant lead-time advantages.

How Roivant Sciences Could Score Big Wins Through High-Stakes IP Battles with Pharma Giants!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Our long-term outlook remains neutral on the S&amp;P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023.</li>
<li>Since late-July discussed expectations for a 1-to 4-month pullback/consolidation on SPX and QQQ; now it's likely to last closer to four months, and potentially 4- to 6-months from 7/17/24.</li>
<li>At that point the market will decide which way this consolidation resolves. Throughout this pullback we have said that this consolidation could end up being a significant topping pattern.</li>
</ul>


Our long-term outlook remains neutral on the S&amp;P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023.
Since late-July discussed expectations for a 1-to 4-month pullback/consolidation on SPX and QQQ; now it's likely to last closer to four months, and potentially 4- to 6-months from 7/17/24.
At that point the market will decide which way this consolidation resolves. Throughout this pullback we have said that this consolidation could end up being a significant topping pattern.


Upgrading Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow

United States

Roivant Sciences Ltd. operates as a healthcare company. The Company offers investigational drugs in development for therapeutic areas such as dermatology, immunology, and respiratory diseases, as well as provides healthcare technologies which help healthcare institutions share and aggregate data. Roivant Sciences provides services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Roivant Sciences Ltd (ROIV US)

Roivant Sciences: How Its Unique Deal Structure With Pfizer Could Shape Long-Term Value!

Roivant Sciences reported significant clinical progress during its third quarter ended December 31, 2025, notably with positive Phase II results...

Baptista Research

Roivant Sciences: From Batoclimab Breakthroughs to Global Trials—A Rising Contender in Autoimmune Therapeutics!

Roivant's latest quarter represents a mixed bag of significant achievements and ongoing challenges. The company is progressing with multiple...

Baptista Research

Roivant Sciences: An Insight Into The Progress in Brepocitinib Trials & Key Growth Levers!

Roivant presented its financial results for the first quarter ending June 30, 2025, reflecting a period described as relatively quiet but setting...

Baptista Research

How Roivant Sciences Could Score Big Wins Through High-Stakes IP Battles with Pharma Giants!

Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts. The...

Baptista Research

Upgrading Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow

Upgrading Staples $XLP, Real Estate $XLRE, Health Care $XLV to Overweight; List of Concerns Continues to Grow; Dow $DJI, Equal-Weight S&P 500 $RSP,...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)